Healthcare Industry News: Frova
News Release - May 12, 2016
Mylan Launches Generic Frova(R) TabletsHERTFORDSHIRE, England and PITTSBURGH, May 12, 2016 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's FrovaŽ Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used to treat acute migraine headaches in adults.
Frovatriptan Succinate Tablets 2.5 mg had U.S. sales of approximately $88.3 million for the 12 months ending March 31, 2016, according to IMS Health.
Currently, Mylan has 260 ANDAs pending FDA approval representing $109.1 billion in annual brand sales, according to IMS Health. Forty-seven of these pending ANDAs are potential first-to-file opportunities, representing $37.5 billion in annual brand sales, for the 12 months ending December 31, 2015, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,400 generic and branded pharmaceuticals, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in approximately 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our nearly 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.